Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Consolidation In The Healthcare Marketplace Is Driving Up Costs

In today’s healthcare climate it’s becoming more challenging for hospitals to remain financially viable. This is especially true for stand-alone, independent hospitals. According to Moody’s researchers, median operating cash-flow margins of 160 surveyed hospital systems dropped from 9.5% in 2016 to 8.1% in 2017.[1] What’s causing the decrease in profitability? Higher labor and supply costs,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In today’s healthcare climate it’s becoming more challenging for hospitals to remain financially viable. This is especially true for stand-alone, independent hospitals. According to Moody’s researchers, median operating cash-flow margins of 160 surveyed hospital systems dropped from 9.5% in 2016 to 8.1% in 2017.[1] What’s causing the decrease in profitability? Higher labor and supply costs, higher drug costs, and lower reimbursement from commercial and government payers. If you’re a small hospital with a tight budget, then you’ve probably entertained the idea of consolidating with a larger system with hopes of controlling costs and growing margins. But the data suggests that both financially and in terms of patient care, consolidation might not be the ideal solution.

The Effects of Consolidation

Across the country, large corporate organizations are snapping up smaller healthcare independents. Today, two in three U.S. hospitals are part of a multi-hospital system. In addition, 1,035 of the 4,840 community hospitals in the U.S. are owned by private investors – that’s 21.4%, up from 16% ten years ago.[2] Unfortunately, hospital consolidation usually does not create the financial efficiencies independent hospitals hope to gain when they agree to an acquisition.

Acquired hospitals should manage their expectations as evidence shows they can realize just a 1.5% gain in marginal efficiency following a merger.[3] Studies also reveal that the average price of hospital services increases 6%−18% as a consequence of these mergers.[4] Consolidation typically results in a rise of prices through facility fees and other fixed costs. Not only is consolidation bad for prices, it can also negatively impact patient care. When hospitals consolidate they concede their independence and are no longer free to make decisions they feel are best for their community, and instead must defer community decisions to a larger corporate entity. 

Collaboration – an Alternative to Consolidation

By many measures, regional coalitions, like TPC, can be a superior alternative to consolidation. Uniting together in healthcare collaboration allows hospitals to aggregate volume without having to merge assets or concede their independence. A majority of the value is achieved through a shared purpose and willingness to act as a system. As a result, hospitals enjoy greater purchasing power and improved supply chain efficiency all while keeping care local and affordable. As supply costs can account for 25-30% of a hospital’s operating budget, with costly Physician Preference Items (PPI) accounting for up to 60% of supply spend, a collaborative effort can drive enhanced value and improved performance, even in complex categories. As a result, collaborative partner hospitals can realize a 20% decrease in supply costs.[5]

The TPC Model

TPC is a partnership that allows independent community hospitals to aggregate their volume to contain costs and leverage their collective strength and size as if they were a single entity. By collaborating, TPC Member hospitals have driven to improve their individual and combined financial, operational and clinical performance. They work together in supply chain, purchased services and revenue cycle to achieve more together than they could alone. In addition, TPC clinical and administrative leaders become part of a virtual network in which they can share best practices and drive better decision making in order to improve patient outcomes and satisfaction. By aligning with like-sized, like-minded facilities, Members benefit from economies of scale, pooled resources and collective expertise.

Stronger Together. Superior Results. Visit us online to learn more about TPC today!

[1] http://www.paulkeckley.com/the-keckley-report/2018/9/11/does-a-hospitals-ownership-matter

[2] http://www.paulkeckley.com/the-keckley-report/2018/9/11/does-a-hospitals-ownership-matter

[3] https://www.healthleadersmedia.com/strategy/how-much-can-ma-cut-costs-lower-your-expectations

[4]https://www.ncci.com/Articles/Pages/II_Insights_QEB_Impact-of-Hospital-Consolidation-on-Medical-Costs.aspx

[5]https://static1.squarespace.com/static/52cd8717e4b02c4c62599d9a/t/58d521a1be659456292aada2/1507043003253/TPC_Supply+Chain+World_Spring+2017.pdf

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512